Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Roche is betting on gene therapies. Photo: Fabrice Coffrini/AFP via Getty Images
Roche, the Swiss-based pharmaceutical conglomerate, is acquiring Spark Therapeutics in a $4.8 billion all-cash deal. The Wall Street Journal first reported the buyout.
Why it matters: Pharmaceutical companies see promise in gene therapies and are willing to pay a large premium for them, but the treatments also come with record-high price tags. Spark has an $850,000 gene therapy to treat a rare eye condition, and a separate product is in the works for hemophilia.